The Business Development & Strategy group works to commercialize intellectual property generated by Fred Hutch researchers so our discoveries and innovations can contribute to better cancer care at the clinic level. We seek industry partners who share our drive to innovate, collaborate and accelerate development of new inventions and approaches. We also cultivate partnerships with philanthropic supporters, research colleagues and policymakers to extend the reach of our scientific advances.
Our areas of focus include:
Our researchers have developed antibodies that deliver targeted radioimmunotherapy and avoid systemic toxicity.
Get fast, non-exclusive access to Fred Hutch technology including software, questionnaires, and biological materials such as antibodies, cell lines and mouse models.
Founded in 2009 by two young Fred Hutch researchers — computational biologist Harlan Robins and molecular biologist and geneticist Chris Carlson — Adaptive Biotechnologies has quickly become a leader in high-throughput DNA sequencing of immune system T cells and B cells for research and diagnostic purposes. In 2018, Adaptive announced a partnership with Microsoft Research to combine its sequencing technology with machine learning and artificial intelligence, with the goal of mapping the entire human immune system and eventually developing a universal blood test to detect any diseases a person’s body may be fighting.
Juno Therapeutics was founded in 2013 as a collaboration between Fred Hutch, Memorial Sloan Kettering Cancer Center and Seattle Children’s Research Institute, combining cutting-edge immunotherapy expertise from all three institutions. With $120 million in Series A private investment funding, Juno was one of the largest biotech launches in history. Juno is now Bristol Myers Squibb, where teams are working to develop innovative T-cell therapies to treat a broad range of cancers. Building on Juno's transformative research, Bristol Myers Squibb launched its first commercially approved CAR T-cell therapy in February 2021.
Founded in 2014, Faraday Pharmaceuticals is advancing pioneering research from Mark Roth’s lab at Fred Hutch on how salts can temporarily shift a person’s metabolism to protect against injury when blood rushes back to a damaged area after circulation has stopped — such as after a heart attack. Roth, a 2007 MacArthur Foundation “genius” grant recipient, has served as president of the company and a member of the board of directors since its founding.
823 Yale Ave. N.
Seattle, WA 98109
Visitors can park in the visitor parking lot adjacent to the Yale Building.